Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis

14 Jan 2006

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Research on Leishmaniasis Studies
Share to Trypanosoma species research and implications
Share to Vector-Borne Animal Diseases

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 16504562
DOI: 10.1016/j.micinf.2005.10.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MVA-LACK as a safe and efficient vector for vaccination against leishmaniasisPMID 16504562Read ↗

Next-Generation Leishmanization: Revisiting Molecular Targets for Selecting Genetically Engineered Live-Attenuated LeishmaniaSemantic proximity Read ↗

<i>Leishmania</i>vaccines: progress and problemsSemantic proximity Read ↗

Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasisSemantic proximity Read ↗

The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine CandidatesSemantic proximity Read ↗

Immunogenicity Evaluation of a Novel Lentiviral Vaccine Expressing Multi- Epitope Against of Leishmania Major in BALB/c MiceSemantic proximity Read ↗

Live attenuated Leishmania vaccines: a potential strategic alternativeSemantic proximity Read ↗

Safety, immunogenicity, and efficacy of a gentamicin-attenuated Leishmania major vaccine in an open-label clinical vaccine trialSemantic proximity Read ↗

Centrin-deficient <i>Leishmania mexicana</i> confers protection against Old World visceral leishmaniasisSemantic proximity Read ↗

DNA Integration in Leishmania Genome: An Application for Vaccine Development and Drug Screening.Semantic proximity Read ↗

Intradermal Synthetic DNA Vaccination Generates Leishmania -Specific T Cells in the Skin and Protection against Leishmania majorSemantic proximity Read ↗

A Second Generation Leishmanization Vaccine with a Markerless Attenuated <i>Leishmania major</i> Strain using CRISPR gene editingSemantic proximity Read ↗

A heterologous prime–boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.